Aktienanalyse zu Pulmatrix Inc (PULM)PULMPulmatrix Inc

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pulmatrix Inc is not a good buy right now due to significant financial losses and declining performance indicators. The stock has a current price of $1.37, with a year-to-date change of -39.31% and a one-year change of -71.60%. The company reported a Q1 EPS of -0.32 and has been experiencing consistent net losses, with a net income of -$1,172,000 in Q1 2026. The main risk is the company's liquidity pressure, as cash and cash equivalents have decreased from $4.1 million to $3.3 million, indicating potential operational challenges.

1 analysts cover PULM: 1 rate it Buy, 0 Hold and 0 Sell.